Feedback / Questions
IONIS-FXI-LRx - Ionis, Bayer
IONIS-FXI-LRx: Initiation of P2b RE-THINc ESRD (NCT04534114) trial in patients with end stage renal disease in 2020
(Ionis Pharmaceuticals)
-
Sep 3, 2020 -
Cardio-Renal Franchise Webcast
Trial initiation date
•
Renal Disease
https://ir.ionispharma.com/static-files/338f1c69-4d49-42a3-ba7d-c01734248df8
Sep 3, 2020
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious